this is a navigational image map, please load this image to continue.


J Tuttle; LD Knoll; R Schmidt; J Susset; and N Zinner; Lexington, KY, Nashville, TN, Denver CO, Providence, RI and Torrance, CA; for the Ditropan® XL Study Group (Presented by Dr. Tuttle)

INTRODUCTION -- Urge incontinence (UI) is socially and professionally debilitating. Protective pad use may prevent embarrassment but does not alleviate the psychological pain. Pads are expensive, and residual moisture may cause skin irritation resulting in additional healthcare visits. We evaluated the cost savings from reduced pad use during a randomized, double-blind, placebo-controlled trial of a new formulation of oxybutynin (Ditropan® XL).

METHODS -- Female patients (n=50) with UI were treated with once-daily, controlled-release Ditropan® XL (5-15 mg) or placebo in a fixed dose escalation study. Patients recorded UI episodes and daily pad use in a diary. Pad price ($0.45 each) was based on a weighted average of the midpoint of pad price for each type of pad used by patients. (Consumer Reports, Oct. 1997) No other direct (medication, healthcare visits) or indirect (work productivity, quality of life) costs were assessed.

RESULTS -- Patients on Ditropan® XL reported a 90% reduction in weekly UI episodes and an 86% reduction in pad use from baseline to study end. These reductions were significant in comparison to placebo (p0.001). The reduction in pad use equates to a yearly savings of $224.96/patient, excluding cost of medication.

Endpoint/week Baseline Study End % Change
Pad use      
Ditropan XL 11.4 1.6 86%
Placebo 15.2 9.6 37%
UI Episodes      
Ditropan XL 16.4 1.6 90%
Placebo 22.3 10.9 49%

CONCLUSIONS -- These results may help elucidate the cost-benefit relationship between medical therapy and other coping mechanisms for UI.

Source: 1999 AUA Meeting

this is a navigational image map, please load this image to continue.